SARS-CoV-2 spike antigen quantification by targeted mass spectrometry of a virus-based vaccine.


Journal

Journal of virological methods
ISSN: 1879-0984
Titre abrégé: J Virol Methods
Pays: Netherlands
ID NLM: 8005839

Informations de publication

Date de publication:
05 2022
Historique:
received: 22 11 2021
revised: 17 02 2022
accepted: 18 02 2022
pubmed: 27 2 2022
medline: 16 3 2022
entrez: 26 2 2022
Statut: ppublish

Résumé

The spike glycoprotein mediates virus binding to the host cells and is a key target for vaccines development. One SARS-CoV-2 vaccine is based on vesicular stomatitis virus (VSV), in which the native surface glycoprotein has been replaced by the SARS-CoV-2 spike protein (VSV-ΔG-spike). The titer of the virus is quantified by the plaque forming unit (PFU) assay, but there is no method for spike protein quantitation as an antigen in a VSV-based vaccine. Here, we describe a mass spectrometric (MS) spike protein quantification method, applied to VSV-ΔG-spike based vaccine. Proof of concept of this method, combining two different sample preparations, is shown for complex matrix samples, produced during the vaccine manufacturing processes. Total spike levels were correlated with results from activity assays, and ranged between 0.3-0.5 μg of spike protein per 10

Identifiants

pubmed: 35217103
pii: S0166-0934(22)00045-3
doi: 10.1016/j.jviromet.2022.114498
pmc: PMC8863330
pii:
doi:

Substances chimiques

COVID-19 Vaccines 0
Spike Glycoprotein, Coronavirus 0
Viral Vaccines 0
spike protein, SARS-CoV-2 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

114498

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Références

Anal Bioanal Chem. 2022 Feb;414(5):1949-1962
pubmed: 34981149
BioTech (Basel). 2021 Oct 12;10(4):
pubmed: 35822796
Proc Natl Acad Sci U S A. 1952 Aug;38(8):747-52
pubmed: 16589172
Viruses. 2021 Mar 26;13(4):
pubmed: 33810465
Anal Bioanal Chem. 2021 May;413(13):3501-3510
pubmed: 33768365
ACS Omega. 2021 Jan 26;6(5):3525-3534
pubmed: 33585737
Vaccine. 2021 Aug 23;39(36):5106-5115
pubmed: 34344552
J Proteome Res. 2020 Nov 6;19(11):4407-4416
pubmed: 32697082
Nat Commun. 2020 Aug 27;11(1):4303
pubmed: 32855401
Proteomics. 2020 Jul;20(14):e2000107
pubmed: 32462744
Vaccine. 2021 Nov 26;39(48):7044-7051
pubmed: 34756612
Front Immunol. 2021 Jul 12;12:701501
pubmed: 34322129
Eur J Biochem. 1980 Mar;104(2):469-78
pubmed: 6244951
Nat Commun. 2020 Dec 16;11(1):6402
pubmed: 33328475
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508

Auteurs

Osnat Rosen (O)

Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona, 7410001, Israel. Electronic address: osnatr@iibr.gov.il.

Avital Jayson (A)

Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona, 7410001, Israel.

Eyal Dor (E)

Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona, 7410001, Israel.

Eyal Epstein (E)

Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona, 7410001, Israel.

Arik Makovitzki (A)

Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona, 7410001, Israel.

Lilach Cherry (L)

Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona, 7410001, Israel.

Edith Lupu (E)

Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona, 7410001, Israel.

Arik Monash (A)

Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona, 7410001, Israel.

Sarah Borni (S)

Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona, 7410001, Israel.

Tzadok Baruchi (T)

Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona, 7410001, Israel.

Orly Laskar (O)

Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona, 7410001, Israel.

Shlomo Shmaya (S)

Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona, 7410001, Israel.

Ronit Rosenfeld (R)

Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness Ziona, 7410001, Israel.

Yinon Levy (Y)

Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness Ziona, 7410001, Israel.

Ofir Schuster (O)

Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona, 7410001, Israel. Electronic address: ofirsc@iibr.gov.il.

Liron Feldberg (L)

Department of Analytical Chemistry, Israel Institute for Biological Research, Ness Ziona, 7410001, Israel. Electronic address: lironf@iibr.gov.il.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH